Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 2nd Preview)
-
First FDA approval of a PROTAC in breast cancer
The FDA approved Arvinas and Pfizer’s Veppanu (formerly vepdegestrant) for a defined subgroup of adults with metastatic estrogen receptor–positive, HER2-negative breast cancer that progressed after at least one endocrine therapy and carries ESR1 mutations. Regulatory review was based on the VERITAC-2 trial, where Veppanu improved progression-free survival by nearly three months versus fulvestrant in the approved population. The decision underscores growing clinical validation for targeted protein degradation—medicines that eliminate disease-linked proteins rather than only blocking them—while also narrowing the label to a biology-defined segment where the benefit was demonstrated.
-
SEC-backed guidance on clinical trial data from China
A U.S. House spending committee advanced language that would require a ban on using Chinese clinical trial data in future FDA drug applications, signaling deep congressional concerns about competition and data integrity. While the measure is unlikely to be adopted as written, its movement through committee reinforces pressure on regulators and sponsors to revisit how evidence from China is accepted in the U.S. review process. The proposal adds to an emerging U.S. policy environment where data origin and verification are increasingly central to oncology, rare disease, and specialty drug submissions.
-
FDA committee scrutiny around AstraZeneca’s camizestrant strategy
FDA oncology advisers voted against using AstraZeneca’s oral SERD camizestrant in a new clinical setting proposed for patients with HR+/HER2− metastatic breast cancer. According to the ODAC panel vote, the committee found the evidence did not support a fundamental switch in treatment strategy based on ESR1 mutations detected in circulating tumor DNA, rather than waiting for radiographic progression. The decision highlights continued sensitivity in oncology to trial design and clinical end points when adopting ctDNA-guided treatment selection, even as ESR1 mutation testing becomes more widely used in practice.
-
Axsome expands Alzheimer’s agitation label after FDA approval
The FDA approved Axsome Therapeutics’ Auvelity (AXS-05) for Alzheimer’s disease agitation, expanding the therapy’s label beyond major depressive disorder. The approval gives Auvelity access to a large commercial indication and places a second treatment option on the Alzheimer’s agitation market, alongside existing therapies with different safety profiles. Axsome’s label update also arrives as the company works to defend competitiveness in a crowded neuropsychiatric space where payers and clinicians increasingly distinguish on efficacy and tolerability by patient subgroup.
-
FDA leadership transition at CBER
Vinay Prasad stepped down as head of the FDA’s Center for Biologics Evaluation and Research, with his deputy Katherine Szarama taking over in an acting capacity while the search for a permanent director continues. Szarama’s appointment places an acting leader at the helm of a center that regulates vaccines, gene therapies, and the blood supply—areas where the FDA has faced sustained industry scrutiny. The leadership change follows a period of high-profile regulatory conflicts involving rare disease therapies and rare biologics, and sets a near-term tone for how biologics evidence is evaluated in the coming weeks.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.